With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. | Abiraterone acetate plus prednisone for the Management of Metastatic CastrationResistant Prostate Cancer mCRPC without prior use of chemotherapy Report from a large international real-world retrospective cohort study